Decline in revenue
In fiscal 2017, Valeant Pharmaceuticals (VRX) expects to report revenue of $8.9 billion–$9.1 billion. This projection is based on foreign exchange rates in February 2017. It also includes revenue expected from sales of the company’s skincare products, as Valeant does not expect the divestiture transactions to be completed before the end of 2017.
Wall Street analysts have projected that Valeant’s 2017 revenue would be ~$8.8 billion, which represents a year-over-year (or YoY) drop of ~9.2%. If Valeant manages to surpass these revenue projections in 2017, its share price and that of the First Trust Value Line 100 ETF (FVL) could be positively affected. Valeant makes up about 0.88% of FVL’s portfolio.
Measures to boost revenue
In addition to reducing debt, Valeant is focused on rapidly increasing its top line. The company has launched a new sales force team that will mainly be involved in marketing Xifaxan to primary care practitioners. To learn why this measure was required, please refer to VRX’s Gastrointestinal Segment Saw Robust Revenue Growth in 2016.
Valeant has also cleared up all issues with its Bausch & Lomb Tampa manufacturing facility, which is now ready for re-inspection by the FDA. The company has also recruited a new management team for its dermatology business. In 2016, Valeant entered into an agreement to extinguish a $210 million liability related to its legacy Salix Pharmaceuticals lawsuit. While the proposal will become effective only after court approval, the company has reported this liability provisionally in its financial statements. In the next article, we’ll explore Valeant’s margin growth trends in 2017.
In fiscal 2017, Valeant Pharmaceuticals (VRX) expects to report revenue of $8.9 billion–$9.1 billion. This projection is based on foreign exchange rates in February 2017. It also includes revenue expected from sales of the company’s skincare products, as Valeant does not expect the divestiture transactions to be completed before the end of 2017. Wall Street analysts have […]
To streamline its product portfolio and reduce its debt, Valeant Pharmaceuticals (VRX) announced divestiture plans in 4Q16. This strategy is expected to improve investor sentiment towards Valeant.
After being listed on the NASDAQ (QQQ) on March 29, Lyft (LYFT) stock has traded on a negative note so far.
Coca-Cola (KO) impressed investors with better-than-expected revenue and earnings for the first quarter.
Microsoft (MSFT) announced this month that it had acquired a San Diego startup called Express Logic for an undisclosed amount.
Spirit Airlines is scheduled to report its first-quarter results on April 25. The airline has an impressive record of beating earnings estimates.
On April 23 before the market opened, legacy motorcycle maker Harley-Davidson (HOG) reported its first-quarter earnings results.
Williams Companies (WMB) is scheduled to release its first-quarter earnings on May 1 after the market closes.